9.59
4.10%
-0.41
Pharming Group N.V. ADR stock is currently priced at $9.59, with a 24-hour trading volume of 617.
It has seen a -4.10% decreased in the last 24 hours and a -9.53% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $9.79 pivot point. If it approaches the $9.58 support level, significant changes may occur.
Previous Close:
$10.00
Open:
$9.79
24h Volume:
617
Market Cap:
$673.44M
Revenue:
$245.32M
Net Income/Loss:
$-10.55M
P/E Ratio:
-36.88
EPS:
-0.26
Net Cash Flow:
$-18.77M
1W Performance:
-3.23%
1M Performance:
-9.53%
6M Performance:
-21.84%
1Y Performance:
-14.83%
Pharming Group N.V. ADR Stock (PHAR) Company Profile
Name
Pharming Group N.V. ADR
Sector
Industry
Phone
31 71 524 7400
Address
Darwinweg 24, Leiden
Pharming Group N.V. ADR Stock (PHAR) Latest News
Pharming Group N.V. ADR Stock (PHAR) Financials Data
Pharming Group N.V. ADR (PHAR) Revenue 2024
PHAR reported a revenue (TTM) of $245.32 million for the quarter ending December 31, 2023, a +19.30% rise year-over-year.
Pharming Group N.V. ADR (PHAR) Net Income 2024
PHAR net income (TTM) was -$10.55 million for the quarter ending December 31, 2023, a -177.14% decrease year-over-year.
Pharming Group N.V. ADR (PHAR) Cash Flow 2024
PHAR recorded a free cash flow (TTM) of -$18.77 million for the quarter ending December 31, 2023, a -191.63% decrease year-over-year.
Pharming Group N.V. ADR (PHAR) Earnings per Share 2024
PHAR earnings per share (TTM) was -$0.16 for the quarter ending December 31, 2023, a -188.89% decline year-over-year.
About Pharming Group N.V. ADR
Pharming Group N.V., a specialty pharmaceutical company, develops and manufactures biopharmaceutical products in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema in Europe, the United States, Israel, and South Korea. It also engages in the development of recombinant human factor VIII (rhFVIII) for the treatment of haemophilia A; and protein replacement treatments for enzyme-deficiency disorders, such as pompe and fabry diseases, as well as products for acute kidney injury. The company has partnerships with China State Institute of Pharmaceutical Industry and the Chengdu Institute of Biological Products for the development of new products; and development collaboration and license agreement with Novartis to develop and commercialize leniolisib (CDZ173), a small molecule phosphoinositide 3-kinase delta inhibitor to treat patients with activated phosphoinositide 3-kinase delta syndrome. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Cap:
|
Volume (24h):